You are here: Industry Insights > MorphoSys

News List

Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Ly firstwordpharma
August 27, 2021
Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi® (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy.
MorphoSys to acquire Constellation Pharmaceuticals for $1.7bn pharmaceutical-technology
June 04, 2021
MorphoSys has signed a definitive agreement to acquire Constellation Pharmaceuticals for a total equity value of $1.7bn or $34 per share, in cash.
I-Mab, MorphoSys Announce First Patient Dosed in Study of TJ210/MOR210 for Advanced Cancer americanpharmaceuticalreview
February 02, 2021
I-Mab and MorphoSys announced the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with relapsed or refractory ...
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer prnasia
January 26, 2021
I-Mab, and MorphoSys today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with relapsed ...
MorphoSys, I-Mab Announce IND Application Clearance for Advanced Cancer Treatment americanpharmaceuticalreview
September 27, 2020
MorphoSys and I-Mab jointly announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or ...
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer prnasia
September 18, 2020
MorphoSys AG and I-Mab jointly announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or ...
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug pharmaceutical-technology
January 15, 2020
Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US company Incyte to continue the global development and commercialisation of the former’s tafasitamab (MOR208) for B-cell malignancies.
LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics pharmafocusasia
December 03, 2018
LEO Pharma A/S, a global leader in medical dermatology, and MorphoSys AG today announced an expansion of their existing strategic alliance to include......
I-Mab Biopharma, MorphoSys declares China IND Submission of monoclonal antibody biospectrumasia
August 10, 2018
The company has Submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma.
Novartis pays €95M to bag dermatitis drug from Galapagos, MorphoSys fiercebiotech
July 23, 2018
Novartis is set to pay €95 million ($110 million) upfront for the global rights to Galapagos and MorphoSys’ anti-IL-17C antibody MOR106.

Previous page 1 2 Next page